论文部分内容阅读
目的探讨以自身树突状细胞(DC)和细胞因子诱导的杀伤细胞(CIK)为效应细胞的过继免疫联合沙利度胺(Thd)治疗复发难治性多发性骨髓瘤(MM)的临床疗效。方法回顾性选择48例诊断明确的复发难治性MM患者作为研究对象,其中对照组24例,接受单纯Thd维持治疗;免疫组24例,接受DC-CIK联合Thd治疗。研究Thd对CIK表型和DC-CIK骨髓瘤细胞杀伤效应的影响,比较两组患者的临床疗效。结果 Thd作用后,CIK表型增强,DC-CIK对U266的杀伤率明显提高;治疗后免疫组患者较之对照组患者生活质量改善,临床疗效提高(P<0.05);结论 DC-CIK过继免疫联合Thd治疗复发难治性MM有良好的临床疗效和应用价值。
Objective To investigate the clinical efficacy of adoptive immunization with self dendritic cells (DCs) and cytokine-induced killer cells (CIKs) as effector cells in combination with thalidomide (Thd) in the treatment of recurrent refractory multiple myeloma (MM) . Methods Retrospectively selected 48 cases of relapsed and refractory MM patients with definite diagnosis as the research object. Among them, 24 cases in the control group received simple Thd maintenance therapy and 24 cases in the immunized group received DC-CIK combined with Thd treatment. To investigate the effect of Thd on CIK phenotype and cytotoxicity of DC-CIK myeloma cells, and to compare the clinical efficacy of the two groups. Results After treatment with Thd, the phenotype of CIK was enhanced and the killing rate of U266 by DC-CIK was significantly increased. After treatment, the immunized group improved compared with the control group with improved clinical efficacy (P <0.05). Conclusion DC-CIK adoptive immunity Combined Thd relapse refractory MM has a good clinical efficacy and application value.